Merck & Co., Inc. (0QAH.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:06PM BST
| Previous close | 125.20 |
| Open | 126.10 |
| Bid | 121.00 x N/A |
| Ask | 131.40 x N/A |
| Day's range | 124.95 - 126.49 |
| 52-week range | 99.15 - 133.08 |
| Volume | |
| Avg. volume | 88,559 |
| Market cap | 320.235B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 103.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.92 (2.83%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
RAHWAY, N.J., July 01, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation ("Orion") today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
- Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
RAHWAY, N.J., July 01, 2024--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
- Business Wire
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J., June 28, 2024--Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
© 2024 Yahoo. All rights reserved.